GREENWICH, Conn.–(BUSINESS WIRE)–Life Science Pharmaceuticals, Inc. announced today that it has entered into a license agreement with Abbott to develop Antibody 806, which may prove to be an important tool in the fight against cancer.
The agreement provides Abbott with exclusive worldwide rights to Antibody 806, which targets the clinically validated pathway involving the Epidermal Growth Factor receptor (EGFr). Antibody 806 is differentiated by its unique epitope targeting a transitional form of EGFr. Financial details of the agreement were not disclosed.
Antibody 806 has demonstrated the ability to target and bind to EGFr while showing essentially no targeting of normal tissues. Applications for 806 include multiple forms of cancer and certain non-cancerous diseases. The 806 antibody was generated by Dr. Lloyd Old and his team at the New York Branch of the Ludwig Institute for Cancer Research (LICR). The antibody was then characterized in conjunction with the LICR’s Branches in New York, San Diego and Melbourne, Australia. The first-in-man clinical trial led by Dr Andrew Scott was sponsored and conducted by the LICR at its Melbourne Center.
“We are delighted to have Abbott as our development partner,” stated James Fiore, president and CEO of Life Science Pharmaceuticals. “We are very impressed with the company’s technological capabilities and its commitment to developing class-leading antibodies.”
About Life Science Pharmaceuticals
Life Science Pharmaceuticals, Inc. (LSP) is a biopharmaceutical company dedicated to developing drugs for unmet or underserved medical needs. LSP and the Ludwig Institute for Cancer Research have entered into a strategic collaboration to develop cancer therapeutics. LSP monoclonal antibodies targeting melanoma and colon cancer are currently in clinical development. LSP continually seeks to acquire novel, early-stage product candidates for pre-clinical and clinical development.